Landscape Capital Management L.L.C. Buys New Position in Nektar Therapeutics $NKTR

Landscape Capital Management L.L.C. bought a new stake in shares of Nektar Therapeutics (NASDAQ:NKTR) in the fourth quarter, HoldingsChannel.com reports. The institutional investor bought 60,431 shares of the biopharmaceutical company’s stock, valued at approximately $2,555,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in NKTR. AQR Capital Management LLC raised its holdings in shares of Nektar Therapeutics by 336.9% during the first quarter. AQR Capital Management LLC now owns 3,640,851 shares of the biopharmaceutical company’s stock valued at $2,463,000 after acquiring an additional 2,807,595 shares in the last quarter. Farallon Capital Management LLC bought a new position in Nektar Therapeutics in the third quarter worth $45,008,000. Two Seas Capital LP bought a new position in Nektar Therapeutics in the fourth quarter worth $31,506,000. Prosight Management LP bought a new position in Nektar Therapeutics in the fourth quarter worth $23,450,000. Finally, Two Sigma Investments LP raised its holdings in Nektar Therapeutics by 446.9% in the third quarter. Two Sigma Investments LP now owns 434,237 shares of the biopharmaceutical company’s stock worth $24,708,000 after purchasing an additional 354,842 shares in the last quarter. Institutional investors own 75.88% of the company’s stock.

Nektar Therapeutics Price Performance

Nektar Therapeutics stock opened at $59.38 on Monday. Nektar Therapeutics has a one year low of $7.99 and a one year high of $109.00. The stock has a market capitalization of $2.01 billion, a PE ratio of -7.05 and a beta of 1.13. The business’s fifty day moving average is $74.59 and its 200 day moving average is $62.24.

Nektar Therapeutics (NASDAQ:NKTR) last released its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported ($1.82) EPS for the quarter, missing the consensus estimate of ($1.58) by ($0.24). Nektar Therapeutics had a negative net margin of 284.18% and a negative return on equity of 85.40%. The business had revenue of $10.86 million for the quarter, compared to analysts’ expectations of $10.69 million. As a group, sell-side analysts expect that Nektar Therapeutics will post -9.45 EPS for the current fiscal year.

Insider Activity at Nektar Therapeutics

In related news, CEO Howard W. Robin sold 444 shares of the stock in a transaction on Tuesday, May 19th. The stock was sold at an average price of $65.51, for a total transaction of $29,086.44. Following the sale, the chief executive officer directly owned 75,045 shares of the company’s stock, valued at $4,916,197.95. This trade represents a 0.59% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 2.50% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of research firms have issued reports on NKTR. Jefferies Financial Group reiterated a “buy” rating on shares of Nektar Therapeutics in a report on Wednesday, April 22nd. Citigroup increased their price objective on Nektar Therapeutics from $123.00 to $151.00 and gave the stock a “buy” rating in a report on Tuesday, April 21st. Piper Sandler increased their price objective on Nektar Therapeutics from $105.00 to $192.00 and gave the stock an “overweight” rating in a report on Friday, May 8th. HC Wainwright increased their price objective on Nektar Therapeutics from $165.00 to $185.00 and gave the stock a “buy” rating in a report on Monday, April 20th. Finally, Wedbush decreased their price objective on Nektar Therapeutics from $95.00 to $80.00 and set a “neutral” rating for the company in a report on Monday, May 11th. Nine analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $149.63.

Nektar Therapeutics Profile

Nektar Therapeutics (NASDAQ:NKTR) is a biopharmaceutical company dedicated to discovering and developing novel drug candidates through its proprietary chemistry and immunology platforms. The company focuses on polymer conjugate technology, which enables the creation of longer-acting versions of existing drugs, and on T-cell modulatory therapies aimed at harnessing the body’s immune system to treat cancer and other serious diseases.

Nektar’s product portfolio and pipeline include a range of clinical-stage and partnered programs.